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Abstract
Cannabinoids have long been a part of human culture and medicine, and more recently have
been rediscovered for their potential use in the management of rheumatic disease pain. The
objective of this review was to evaluate the known clinical effectiveness of cannabidiol
treatment for rheumatic disease related pain. The legality and current regulation of these
products was also reviewed to establish the current status of federal and state rules regarding
their clinical use. Basic definitions of the terms used to differentiate cannabidiol from other
cannabinoid products was also outlined. A systematic literature search was then conducted to
explore the current pool of evidence pertaining to the defined phenomena of interest and
clinical question. Five electronic databases were selected to generate a comprehensive
selection of evidence. Twenty-one articles were identified and evaluated for appropriateness
of fit within the defined inclusion and exclusion criteria. Articles relating to the use of
cannabidiol in any form for the treatment of rheumatic disease pain in adults were included.
Research articles pertaining to non-rheumatic diseases, psychiatry, children, adolescents,
medical cannabis, or tetrahydrocannabinol alone were excluded. A total of nine studies met
inclusion criteria. Findings from those studies concluded that current evidence is lacking in
quality, quantity, and in key factors regarding the efficacy, tolerability, and safety of
cannabidiol for rheumatic disease relief pain. Furthermore, due to the lack of evidence
evaluating cannabidiol use for rheumatic disease pain, additional clinical studies are needed
to evaluate their usefulness. Best practice and research recommendations were also proposed
based of the systematic review and current body of evidence.
Keywords: cannabidiol, cbd oil, rheumatic disease, treatment, analgesia, safety,
effectiveness
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Exploring the Effectiveness of Cannabidiol Use in Rheumatic Disease Pain:
A Systematic Review
Cannabinoids have been a part of human culture for the past millennia and used for
various medicinal purposes (Sarzi-Puttini et al., 2019). Presently, the use of cannabinoids for
chronic pain relief is rapidly increasing as the unrestricted availability of these products steadily
surges. It is a frequent occurrence to find products containing cannabinoids sold online or at any
local convenience or grocery store claiming to aid the management of many conditions including
arthritis pain relief. Additionally, the marketing of the cannabidiol or CBD for arthritis pain relief
has also exponentially increased, leading to the dissemination of scientifically unsubstantiated
claims. Within the scientific community, many uncertainties and controversies remain regarding
the role of cannabinoids for the management of rheumatic pain (Perrot & Trouvin, 2019). This is
further compounded by the confusion between different forms of cannabis plants and products
such as herbal cannabis, medical cannabis, and cannabinoids (Perrot & Trouvin, 2019).
Therefore, it is important to differentiate these products and look beyond the anecdotal claims as
these ancient drugs are now being rediscovered and reconsidered as potential modern analgesic
therapies by patients (Perrot & Trouvin, 2019). This review aims to evaluate the current body of
clinical evidence available to support the clinical use of CBD oil for rheumatic disease pain relief
in order to suggest clinical practice recommendations.
Background
Cannabinoids have long been used for recreational, medicinal, and even ceremonial
purposes (Sarzi-Puttini et al., 2019). Early uses of cannabinoids for medicinal purposes in
conditions such as rheumatic pain, constipation, and even malaria, date back to 28th century BC
(Sarzi-Puttini et al., 2019). More recently cannabinoid products have been used around the world
for its therapeutic properties in chronic pain relief, epilepsy, and opioid addiction. Additionally,
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social or recreational use of cannabis products is growing as many states are legalizing their use
despite the paucity of evidence regarding their safety and efficacy (Sarzi-Puttini et al., 2019).
Cannabinoids are natural compounds derived from the cannabis plant family. There are
more than 100 known cannabinoids; the most common cannabinoids used are
tetrahydrocannabinol (THC) and CBD. Derived from the cannabis sativa plant, CBD has been
used for centuries in various medicinal preparations for the treatment of chronic pain, a cardinal
symptom of many rheumatological diseases (Sarzi-Puttini et al., 2019). Rheumatic diseases, such
as osteoarthritis, represent a group of painful conditions where conventional analgesics show
poor efficacy and inadequate long-term control of pain relief (Perrot & Trouvin, 2019). Thus,
CBD oil has grown to be a popular option as a potential new therapeutic alternative for
rheumatic pain (Perrot & Trouvin, 2019). The rationale for its use in arthritis is based not only on
its analgesic effects, but also on its anti-inflammatory effects and immunomodulatory activity
(Perrot & Trouvin, 2019). Due to its lack of psychoactive properties, CBD oil is a seemingly safe
choice for patients who are seeking alternatives for pain relief (Sarzi-Puttini et al., 2019).
Nevertheless, centuries old use, the absence of psychotropic properties, and lack of other
effective therapies is not sufficient evidence to prove that CBD oil is a useful or safe treatment
for rheumatic pain (Sarzi-Puttini et al., 2019).
The legality, safety, and efficacy of CBD is often called into question as many healthcare
providers are uncertain of the existing supportive evidence and current regulation of CBD oil.
Skepticism of the effectiveness of CBD oil, stemming from the lack of current evidence, has left
many health care professionals calling for more validation to be done regarding its usefulness in
clinical practice (Sarzi-Puttini et al., 2019). Likewise, validating patient reported treatments that
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improve rheumatic disease pain necessitates further clinical studies of CBD oil to determine if it
plays any clinical role in the management of these disorders.
Additionally, as the cannabinoid industry explodes into the mainstream consumer market,
associated terminology and understanding of specific terms is often misunderstood and misused.
Commonly used terms include cannabinoids, cannabidiol, cannabis, hemp, marijuana, hemp seed
oil, CBD oil, medical marijuana, THC, and cannabis oil. Often, many of these terms are used
interchangeably, leading to confusion for patients and providers alike. Lastly, many products
have been found to contain a mixture of cannabinoids with mislabeled concentrations, creating
uncertainty surrounding which cannabinoid may be providing relief or found to have harmful
side effects.
Definitions
Familiarity with commonly used terminology of CBD products is necessary to
understand the clinical phenomenon of interest as their various terms used. Knowledge of the
definitions of these terms is important to differentiating CBD from other cannabinoid products.
The Endocannabinoid System
The endocannabinoid system or ECS, is a newly discovered system within the human
body. It acts as a homeostatic regulator of functions within the brain, cardiovascular system,
digestive track, liver, and even bone (Russo, 2016). This system is comprised of a triad of
cannabinoid receptors including CB1, CB2, TRPV1, endogenous cannabinoids such as
anandamide, and exogenous cannabinoids such as CBD or THC (Russo, 2016).
Cannabinoids
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Cannabinoids are compounds derived from the cannabis plant family. These naturally
occurring chemical compounds are the active ingredients found in cannabinoid products
(VanDolah et al., 2019). These compounds include THC and CBD.
Tetrahydrocannabinol
THC is the primary psychoactive cannabinoid found in the Cannabis sativa L. plant. THC
is a phytocannabinoid or plant-derived cannabinoid that is a CB1 receptor agonist, known for
producing intoxicating CNS effects (VanDolah et al., 2019).
Cannabidiol
This is a non-intoxicating cannabinoid extracted from the flowers of the female Cannabis
sativa L. plant and is used for its therapeutic properties in pain relief (VanDolah et al., 2019).
CBD oil has become especially popular as an over the counter medication because of its low
THC levels resulting in medical benefits such as pain relief without the euphoric sensations
associated with marijuana (VanDolah et al., 2019). It binds to the TRPV1 receptor and does not
have any intoxicating effects.
Hemp
Hemp is a species of the Cannabis sativa L. plant that contains less than 0.3% THC.
Often its fibers are used for clothing and its oil is used in cosmetic products. It does not contain
enough THC to have psychoactive properties, yet it does contain CBD. As of January 1, 2020,
products containing CBD derived from hemp can be legally sold under Minnesota state law
(Minnesota Department of Agriculture, 2020).
Hemp Seed Oil
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This is created from the seeds of the hemp plant and does not contain any cannabinoids.
It is often used as a nutritional supplement or in clothing and fibers. It also contains omega-6 and
omega-3 fatty acids and other antioxidants (VanDolah et al., 2019).
Cannabis Oil
Cannabis oil is derived from the marijuana plant which is also of the same plant species
Cannabis sativa L. Its THC levels are directly related to genetic differences in cannabis sativa
plants and specific growing techniques. Cannabis oil contains high levels of THC and is only
legal to produce by medical cannabis manufacturers licensed by the Minnesota Department of
Health (Minnesota Department of Agriculture, 2020).
Clinical Phenomenon of Interest
Cannabidiol, or CBD, seems to be available almost everywhere. It is marketed as a
product to help with pain, anxiety, and even seizures. There is significant public interest in
cannabis derived products despite many unanswered questions regarding the safety, efficacy, and
quality of products containing CBD. Additionally, the U.S Food and Drug Administration (FDA)
only recognizes the use of CBD products for two rare forms of epilepsy (U. S. Food and Drug
Administration, 2019). Thus, an urgent need for analysis of the current body of evidence and its
findings is crucial to evaluate the safety, efficacy, and potential for adverse effects of CBD oil.
While some patients may feel that these products are safe, rigorous scientific studies
demonstrating their effectiveness and safety are insufficient. Furthermore, providers are often
asked by their patients if these products work and if there are any known benefits. Therefore,
providers must be astutely aware of scientific evidence regarding the safety and efficacy of CBD
oil. Thus, it is imperative that thorough evaluation of existing CBD oil research is conducted and
evaluated.
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Presently, CBD oil products are being sold as dietary supplements claiming to relieve
arthritis pain yet have not been subject to FDA evaluation or been proven to have any therapeutic
benefit. There is also limited research regarding the appropriate dosage of CBD oil, any food or
drug interactions, or dangerous side effects of CBD oil (FDA, 2019). The FDA has tested the
chemical contents of cannabinoid products sold over the counter and again have found they did
not contain the levels of CBD as indicated on the label (FDA, 2019). There are also reports of
cannabinoid products containing unsafe levels of contaminants such as pesticides, heavy metals,
and THC (FDA, 2019). Thus, the potential for patient harm is undeniable given the lack of
research needed to identify the proper dosage, the inconsistent labeling of CBD oil sold over the
counter, and unproven anecdotal claims associated with these products. The potential to delay
seeking appropriate medical care is also greater for patients using alternative therapies for pain
relief that are not evidenced to be safe and effective.
Clinical Question
The PICO format was utilized to focus the literature search and refine the topic of clinical
interest. In adults experiencing pain due to rheumatic disease (P), how does cannabidiol use (I)
compared to no use of cannabidiol (C) influence pain relief?
Clinical Significance for Advanced Practice
Many health care providers are uncertain about the efficacy, legality, and safety of over
the counter products containing CBD oil used for pain relief. It is imperative that health care
providers have a clear understanding of these aspects and CBD oil’s efficacy in treating
rheumatic disease pain as patients may seek their counsel on the use of these products. A clear
understanding of the clinical research conducted on the chief ingredients found in CBD oil
products is the first step to informing primary care providers about the safety and efficacy. It is
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well known that there are only a small number of clinical research studies conducted and
disseminated regarding CBD oil products, as most research focuses on THC and its primary
target, CB1 receptors (VanDolah et al., 2019). Therefore, this lack of evidence significantly
impacts the potential for advocacy of the use of these products.
Legal and Regulatory Considerations
The sale of over the counter CBD oil products are currently widespread throughout the
United States. With the passage of the 2014 Agricultural Act, the growth of hemp or Cannabis
sativa L. with a THC content of no more than 0.3% was legalized for the purposes of research in
the United States and was removed from the Controlled Substances Act (VanDolah et al., 2019).
It remained illegal, however, to introduce any supplement or food containing CBD into interstate
commerce (VanDolah et al., 2019). Thus, most products were therefore imported from Europe,
processed, and redistributed within the United States to be sold with little regulation (VanDolah
et al., 2019). This led to widespread distribution of unregulated and mislabeled products
commonly seen sold in many retail stores.
As of January 1st, 2020, the sale of over-the-counter hemp products containing CBD oil
containing less than 0.3% THC can be legally sold under Minnesota law (Minnesota Board of
Nursing, 2019). This new regulatory step also aims to reduce mislabeling as labeling conditions
are clearly outlined and required for CBD oil products. The new labeling requirements must now
include an accurate statement of ingredient amounts, a statement of the amount or percentage of
cannabinoids found in each individual dose consumed, and a statement stating that the product
does not claim to diagnose, treat, cure, or prevent any disease (Minnesota Board of Nursing,
2019). The label must also state it has not been evaluated or approved by the FDA unless the
product has been so approved (Minnesota Board of Nursing, 2019).
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Safety and Adverse Effects
Of the few studies conducted examining CBD oil safety, a range of CBD oil doses from
300 milligrams per day for 6 months to 1200 - 1500 milligrams per day for 4 months were used
safely (VanDolah et al., 2019). However, studies with larger numbers of participants have found
associated side effects with the use of CBD oil including somnolence, decreased appetite,
diarrhea, and elevated liver function tests (VanDolah et al., 2019). Furthermore, some drug to
drug interactions have been found as a result of the metabolism of CBD oil by the cytochrome
P450 enzyme system including warfarin and various epilepsy medications (VanDolah et al.,
2019). Lastly, inconsistent branding of the ingredients within these products has included over
labeling CBD content and under labeled THC (VanDolah et al., 2019). As a result, severe
adverse reactions have led to two hospitalizations due to ingestion of these products (VanDolah
et al., 2019).
Methods
A systematic literature search was conducted between the dates of 10/11/19 through
10/25/19 to explore the current evidence pertaining to the defined clinical question. Five
electronic databases were selected to generate a comprehensive selection of evidence. Articles
were then evaluated for appropriateness of fit within the defined inclusion and exclusion criteria.
Search Strategies
To focus on the outlined clinical question, a broad range of applicable key words were
selected and applied when searching all five databases. Boolean operators were also utilized to
combine search terms and broaden the results. Key words were matched within all article text.
This strategy was used to retrieve all studies examined within this review.
Data Abstraction Process
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Databases searched included CINAHL, CENTRAL, ProQuest, PubMed, and PsycINFO.
Detailed database information, general search terms, specific dates, and search restrictions are
included in Table 1 of the attached appendix. Studies were found using search terms including
“CBD oil,” “cannabidiol,” “pain,” “pain relief,” “rheumatic disease,” ” inflammation,” “antiinflammatory,” “treatment efficacy,” “arthritis,” “analgesic,” and “join pain.” Search limits
applied to database searches consist of only peer reviewed articles authored between 2006-2019,
full text available, English language, Adults, Humans, Evidence-based healthcare, literature
review, systematic review, abstract available, and scholarly journals. Article titles were then
reviewed by the author when database searches concluded 10 hits or less. Titles were eliminated
if they contained non-human subjects, children, adolescents, and non-rheumatic diseases. A
complete list of unique matches included within this review are indicated in Table 2 in the
appendix.
Inclusion/Exclusion Criteria
Articles relating to the use of CBD for the treatment of rheumatic disease pain in adults
were included. Relevant studies that reviewed multiple types of cannabinoids individually,
including CBD oil, were also incorporated in order to expand the amount of available literature.
Research that discussed the history of cannabinoids was also incorporated. A total of 9 articles
met inclusion criteria for this analysis. Refer to Table 3 for all reviewed articles with inclusion
criteria rationale.
Research articles pertaining to non-rheumatic diseases such as cancer, hepatic disease,
epilepsy, children, or adolescents were excluded. Studies pertaining only to the use of medical
cannabis or THC were excluded. Topics examining cannabinoid use in psychiatry were also
excluded. Refer to Table 3 for all reviewed articles with exclusion criteria rationale.
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Literature Review Process
Fifty-three studies were identified using keywords and keyword combinations to search
the five databases. Twenty-one studies were further reviewed for a fit with inclusion or exclusion
criteria; 32 studies were duplicates. After evaluation of the final search results, nine studies fit
the inclusion criteria and were included in this literature review. Those studies included one
systematic review of randomized control trials, two randomized control trials, three reviews of
mixed trials, one case study, and two articles of expert opinion. Detailed information regarding
the purpose, sample size, level of evidence, variables, findings, and implications of all nine
included studies are indicated in Table 4 in the appendix.
Literature Review
This literature review aims to identify the current body of evidence pertaining to the
therapeutic use of cannabinoids, specifically CBD, for the treatment of rheumatic disease related
pain. This research related to the effects of CBD on rheumatic disease pain will be synthesized.
After meeting inclusion criteria, the nine studies were evaluated for strength of evidence and
substantiation of therapeutic benefit with the use of CBD on rheumatic disease pain.
Study Characteristics
As described in the literature review process section, the highest level of evidence found
was one level I systematic review while all other evidence discovered was a mixture of level II,
III, VI, and VII. The nine studies included in this review are organized by level of evidence as
follows: one systematic review, two randomized control trials (RCTs), three reviews of mixed
trials, one case study, and two articles of expert opinion. The level I evidence identified by this
systematic review was a systematic review of RCTs, that assessed the outcomes of cannabinoid
use in patient with rheumatic disease. Level II studies consisted of two RCTs. Hunter et al.
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(2018) evaluated the effects of CBD oil on pain and inflammation in osteoarthritis the knee and
Blake et al. (2006) assessed the efficacy of defined dosages of cannabis-based medicine in
rheumatoid arthritis pain. Level III studies comprised of three articles that reviewed mixed
method studies and non-randomized cohort studies. Ark (2016) conducted a literature review of
level II and level III studies examining cannabis or CBD use in rheumatoid arthritis. Bruni
(2018) reviewed current clinical trials regarding cannabinoids and their effects on pain and
inflammation. While, Kraft (2012) explores the clinical data in cannabinoid use for analgesia.
The level VI evidence found consisted of one review of the historical development of research
and current evidence on CBD use in numerous diseases including rheumatoid arthritis and other
inflammatory diseases (Zuardi, 2008). Finally, level VII evidence included two studies of expert
opinion. Miller et al. (2017) provided a historical review of cannabis and expert opinion on
current studies assessing the efficacy of cannabinoids in the treatment of joint pain. Booz (2011)
aimed to review the utility of non-psychotropic CBD in reducing oxidative stress and
inflammation in diseases such as rheumatoid arthritis and neuropathic pain.
Populations Studied
Musculoskeletal pain is one of the most common reasons for primary care visits (Dunphy
et al., 2015). Rheumatic diseases contribute to many musculoskeletal pain complaints in primary
care as they are associated with chronic pain and inflammation. Rheumatic disease consists of
inflammatory and autoimmune conditions that are commonly categorized under the term arthritis
(Mayo Clinic, 2020). Osteoarthritis and rheumatoid arthritis are examples of common chronic,
articular types of rheumatic disease. Osteoarthritis involves the degeneration of cartilage within
joints such as the knee or hip and rheumatoid arthritis affects the synovial membrane within
joints causing pain, swelling, and stiffness (Mayo Clinic, 2020). Patients with rheumatic disease
related arthritis suffer daily from pain, immobility, stiffness, physical deformity, and limited
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range of motion. As many patients with these conditions are seeking relief from the associated
pain and stiffness, both these conditions are the primary focus of this review.
Literature Review
Fitzcharles et al. (2016) conducted a systematic review of the effect of cannabinoids on
the reduction of pain, sleeping difficulties, fatigue, and quality of life associated with rheumatic
diseases. Four randomized control studies met inclusion criteria for the systematic review
conducted by Fitzcharles et al. (2016). Two of those studies focused on fibromyalgia syndrome,
one study examined chronic spinal pain, and the final study examined rheumatoid arthritis. No
randomized control trial involving osteoarthritis was found. Within the single study regarding
rheumatoid arthritis an oral combination spray consisting of CBD 2.5 mg and THC 2.7 mg was
found to be statistically superior compared to placebo (p =0.02) in reducing morning pain with
movement and rest, but not overall pain (Fitzcharles et al., 2016). However, frequent side effects
were reported including dizziness, drowsiness, nausea, and dry mouth along with one serious
side, a fracture, effect as a result of falling (Fitzcharles et al., 2016). It was unclear, however, if
any of these were due to CBD or THC. Ultimately, Fitzcharles et al. (2016) concluded that
currently there is insufficient evidence to recommend any cannabinoid preparations for the
management of pain associated with rheumatic disease. They also caution that rheumatic disease
patients requesting CBD or any cannabis treatment should be made aware of the current absence
of evidence for effect and therefore, these therapies should be reserved for those who have
exhausted all other pain relief options (Fitzcharles et al., 2016).
Blake et al. (2006) conducted a randomized, double blind control trial of 58 patients with
rheumatoid arthritis over the span of five weeks. Using a cannabis-based medicine comprised of
THC and CBD, the effectiveness in relieving pain with movement, pain at rest, morning
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stiffness, and impact on sleep quality was measured (Blake et al., 2006). This study observed a
small but potentially significant analgesic effect with this therapy. Specific to CBD oil, the study
detected a modest suppression of inflammation activity, as measured by the Disease Activity
Score, suggesting some anti-inflammatory properties related to CBD oil (Blake et al., 2006).
These findings suggest some clinical relevance and reinforce the necessity for more detailed
studies regarding efficacy, dosage, and formulation of CBD products (Blake et al., 2006).
Using transdermal synthetic CBD oil gel, Hunter et al. (2018) evaluated the safety and
efficacy of this therapy for the treatment of knee pain due to osteoarthritis in humans. A
randomized, double-blind placebo controlled multiple dose study of 321 patients was conducted
over 12 weeks on adults with knee pain due to osteoarthritis (Hunter et al., 2018). Topically, a
dosage of 250mg twice per day was given versus a placebo (Hunter et al., 2018). Following a
one-week washout period, implemented to allow cessation of any current analgesics and
systemic elimination, a one-week baseline period was conducted to capture daily worst pain
ratings using a 0 to 10 numeric rating scale (Hunter et al., 2018). Weekly thereafter, pain scores
were then captured using the same pain rating scale and evaluated for changes from baseline
ratings during the trial period (Hunter et al., 2018). Adverse effects noted during this trial
included application site dryness and headache (Hunter et al., 2018). After 12 weeks of blinded
treatment, Hunter et al. (2018) found there were no statistically significant differences between
the placebo group and CBD gel treatment group on osteoarthritis related pain relief.
Examining randomized and non-randomized control trials, Ark (2016) evaluated
literature regarding chronic pain due to rheumatoid disease and the utilization of cannabis or
CBD. Three human RCTs were reviewed and limited evidence to support CBD for treatment of
pain caused by inflammatory pathways, autoimmune processes, or neurodegeneration was
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summarized (Ark, 2016). Conclusions drawn from this mixed review indicated that more human
studies are needed to determine the efficacy of CBD oil for the treatment of rheumatic disease
(Ark, 2016).
An abundant amount of patient testimonies exists regarding the anecdotal therapeutic
effects of CBD for pain despite the insufficient amounts of rigorous clinical studies conducted
(Bruni et al., 2018). Thus, Bruni et al. (2018) surveyed current clinical trials regarding
cannabinoids and their effects on pain and inflammation. Additionally, they analyzed various
CBD oil administration and delivery forms, such as transdermal and oral-mucosal routes for
therapeutic benefit (Bruni et al., 2018). Conclusions drawn from this review regarding CBDbased products for therapeutic pain reduction purposes in forms such as oils, tinctures, and
vapors, recommend careful consideration when using these products as any potential health risks
or benefits have not been fully established (Bruni et al., 2018). They caution that while CBD use
by patients is increasing, additional scientific evaluation of CBD is essential in order to
determine quality, safety, and efficacy data (Bruni et al., 2018).
Kraft (2012) acknowledged that there has been a recent resurgence in the medical use of
the cannabis sativa plant for the purpose of analgesia. Thus, Kraft (2012) analyzed clinical data
from human trials of multiple forms of cannabinoids, including CBD oil. They concluded that
due to small sample sizes and short trial durations, findings from these studies were unclear
regarding the analgesic effects of cannabinoids on rheumatic pain (Kraft, 2012). Some
supportive evidence found marginal analgesic effects when used as adjuvant therapies but
recommend that additional well-designed human control studies must be done to confirm these
findings (Kraft, 2012).
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Zuardi (2008) acknowledge that CBD oil has a wide range of potential pharmacological
effects for many conditions including rheumatoid arthritis. The researchers speculate that the
suppressive effects of CBD oil on immune response and along with the production of proinflammatory mediators suggest some usefulness in rheumatic disease pain (Zuardi, 2008).
However, a notable finding from this review indicated that the effects of CBD oil were likely
dose dependent, emphasizing that the lowest most effective dose must be a central factor in
future CBD research (Zuardi, 2008). Additionally, due to the multiple potential mechanisms of
action identified, further research is needed to clarify and underline any potential beneficial
effects of CBD oil (Zuardi, 2008).
Reducing oxidative stress is often a key target for therapeutic uses of CBD oil. Booz
(2011) discussed the recent studies suggesting that CBD may have some utility in reducing
oxidative stress and inflammation within rheumatoid arthritis. They suggest the therapeutic
action of CBD oil is triggered by the suppression of immune response, specifically by inducing
apoptosis of lymphocytes (Booz, 2011). However, the mechanism of action surrounding the antiinflammatory activities of CBD oil remains to be well-defined (Booz, 2011). Early conjecture
suggests this may be the result of interruption within intercellular signaling (Booz, 2011).
Ultimately, given the potentially positive properties such as suspected anti-inflammatory activity,
immunosuppressive actions, and lack of psychotropic effects of CBD oil, further therapeutic
studies regarding the utility of this drug are recommended (Booz, 2011).
Finally, the expert opinion of Miller and Miller (2017) acknowledges that the effects of
herbal cannabinoids in humans with joint pain needs to be more accurately assessed because
many patients are choosing to self-medicate with these products. They also recognize that
patients are reporting benefit from the use of cannabinoids, including CBD, and call for more
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rigorous clinical evidence to support these claims (Miller & Miller, 2017). Furthermore, they
point out that it is unclear if CBD alone is helpful in producing analgesic effects as limited
examination of the effects of individual cannabinoids in patients with rheumatic diseases has
been conducted (Miller & Miller, 2017). Their findings suggest that due to the lack of rigorous
clinical studies, there is not enough data to support CBD oil for the treatment of joint pain
despite the many anecdotal patient statements (Miller & Miller, 2017).
Quality Indicators
Multiple researchers acknowledged the importance of seeking new rheumatic disease
pain analgesics as traditional analgesics show poor efficacy and leave many patients with
uncontrolled rheumatic disease pain. The articles reviewed included contribution from many key
stakeholders including physicians, nurse practitioners, and pharmacists. The hierarchy of
evidence resulting from this review, however, varied in strength and appropriateness to answer
the defined clinical question. The use of true experimental research designs to provide the
highest levels of confidence to answer the clinical question was limited in the current body of
low-quality evidence. Lower level of confidence studies utilizing non-experimental designs were
found to be more prevalent within the literature. Additionally, the two experimental studies
available evaluating the defined clinical question varied largely in sample size and in their
measurement of treatment effects. At present, there are also many confounding variables
identified within the research including mixed patient populations, different cannabinoid
preparations, various formulations, and wide dosing ranges (Bruni et al., 2018). On the other
hand, despite the multiple research designs used, recommendations regarding the use of CBD for
rheumatic disease pain were all together consistent.
Gaps in Literature
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Major gaps in literature stem from the absolute lack of research regarding CBD in
general. At present, very few human studies provide tangible evidence concerning the
appropriate dose, route, frequency, safety, and efficacy of CBD. Furthermore, available human
research studies related solely to CBD oil use for rheumatic disease pain are even more meagre,
as most research has been conducted for its use in conditions such as cancer related pain and
epilepsy. Thus, rigorous human clinical control trials aimed to determine both long and shortterm effects, lowest efficacious dose, most effective route, safety, and risk of adverse effects
must be conducted in order to strengthen the evidence regarding the use of CBD oil for
rheumatic disease pain.
As many studies within this review contained various modes of administration, the most
effective route remains unknown. Additionally, this gap significantly weakens the pool of current
research as parallels are unable to be made amongst data. In addition, this variance further
impedes any supportive evidence validating the lowest efficacious dose with the fewest side
effects. Thus, it remains that additional rigorous evidence is needed to determine the most
efficacious, safe, and efficient mode of administering CBD.
Best practices and recommendations found within this review were not promising
regarding CBD oil use for rheumatic disease pain. Most literature findings resulted in the call for
more rigorous studies to be conducted before any further practice related guidance could be
drawn. In fact, while many studies emphasized the importance of seeking new rheumatic pain
management strategies, none could conclude that CBD oil use for the treatment of rheumatic
disease pain was better than current pain management strategies. Ultimately, the level of
evidence supporting the use of CBD oil in rheumatic disease pain is minimal and therefore,
clinical practice recommendations suggest limited routine use.
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Discussion
Cannabinoids have long been used for recreational and medicinal purposes. More
recently cannabinoid products have been used across the world for their therapeutic properties in
chronic pain relief, epilepsy, and even addiction. Due to its low THC concentration, the
cannabinoid CBD oil has become popular as an over the counter medication for rheumatic
disease pain relief. Notably, regulation of these products is limited, allowing for inconsistent
labeling of CBD oil sold over the counter. However, with the passage of the 2014 Agricultural
Act, the growth of hemp or Cannabis sativa L. with a THC content of no more than 0.3% was
legalized for the purposes of research in the United States and CBD was removed from the
controlled substances act (VanDolah et al., 2019). This has led to state law changes regarding its
sale and new labeling requirements.
Many uncertainties remain regarding the roll of cannabinoids for the management of
rheumatic pain. Despite the paucity of evidence regarding their safety and efficacy, patients
frequently use these products for pain relief for their rheumatic disease. In summary of the
evidence identified for this review, a modest suppression of inflammation activity suggests antiinflammatory and immunomodulating properties of CBD oil and potentially indicates some
clinical relevance (Blake et al., 2006). However, direct correlation to exact mechanisms are not
able to be concluded and therefore only reinforce the need for more detailed studies regarding
efficacy, lowest effective dose, and most appropriate formulation of CBD products (Blake et al.,
2006). Other supportive evidence found indicated marginal analgesic effects when used as
adjuvant therapy and recommended that additional well-designed human control studies must be
done to confirm these findings (Kraft, 2012). On the other hand, some studies found side effects
including dizziness, drowsiness, nausea, and dry mouth, yet it was unclear whether these were
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due to CBD or another ingredient within the product. Additionally, multiple authors pointed out
that any potential health risks or benefits have not been fully established and further research is
needed to explore these areas. A common theme found within all nine articles reviewed indicated
that given the potentially positive properties including anti-inflammatory activity,
immunosuppressive actions, and lack of psychotropic effects, further therapeutic studies
regarding the utility of CBD oil are warranted. While many studies emphasized the importance
of seeking new rheumatic pain management strategies, none could conclude that CBD oil use for
the treatment of rheumatic disease pain was better than current pain management therapies.
To date, the available evidence related to the clinical question is minimal. There are very
few rigorous studies conducted that solely assess the clinical effectiveness of CBD oil for
rheumatic disease related pain. Far more literature containing anecdotal evidence or expert
opinion is available at this time. As safer and more effective alternative therapies for the relief of
rheumatic disease is sought, it is imperative we do our due diligence and scientifically study the
potential CBD oil may provide in pain relief before we advise its routine use. Anecdotal
statements cannot be allowed to supersede evidenced based, high-quality research regarding
CBD nor risk patient harm by recommending its use without scientific proof of its safety. Many
studies within this review brought forward concerns for unknown harms or side effects if careful
examination of CBD oil use for rheumatic disease pain if left undone. Therefore, it is important
to take the time to formulate multiple thorough experimental studies that assess the safety and
efficacy of CBD oil in rheumatic disease pain. Imperatively, these studies must align and analyze
appropriate route, strength, short and long-term effects, side effects, risk for addiction, efficacy
and safety before any recommendations for use can be made.
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Finally, it is imperative that health care providers have a clear understanding of the
efficacy of CBD oil in relieving rheumatic disease pain as patients may seek their counsel on the
use of these products. Many studies within this review acknowledged that due to various modes
of administration, the most effective route and lowest effective dose of CBD remains unknown.
As a result, the research found to date is inconclusive regarding the efficacy of CBD oil for
rheumatic disease pain relief. Thus, it remains that additional rigorous evidence is needed to
determine the most efficacious, safe, and efficient mode of administering CBD. Due to the lack
of congruent evidence found in this review, it is surmised that health care providers should not
advocate for routine use of CBD oil until further rigorous studies are conducted.
Implications for Future
At present, due to the lack of available evidence-based literature needed to answer the
identified clinical question, few proposals for CBD as a future therapy in rheumatic disease pain
are suggested. The following areas have been identified for discussion of necessary future
recommendations and include clinical practice management, patient and provider education, key
research needs, and requests for healthcare policy.
Clinical Practice Recommendations
Maintaining clinical curiosity and a healthy respect for skepticism is key to the
exploration of new pain management options within rheumatic disease. At present, current
traditional analgesic management is inadequate, leaving many patients seeking new therapies for
pain relief. Yet, due to the low quantity and quality of available evidence on the efficacy,
tolerability, and safety of CBD in rheumatic disease pain relief, recommending CBD oil for
routine clinical is not advised (Fitzcharles, 2016). Therefore, CBD oil should only be cautiously
considered as an adjunctive, complementary therapy in the management of rheumatic disease
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pain (Sarzi-Puttini et al., 2019). Until known safety, efficacy, side effects, and confidence in
accurate over the counter drug labeling is observed, providers should prudently address patient
questions regarding routine CBD use for rheumatic disease pain.
Recommendations for Research
CBD is a non-intoxicating and potentially useful substance with increasing patient
interest (VanDolah, 2019). Despite non-FDA approval for therapeutic use, patients continue to
use CBD oil regardless of potential safety concerns, side effects, or lack of evidence supporting
its therapeutic benefit (VanDolah, 2019). This considerably risky choice, especially in patients
with rheumatic disease, stems from the poor pain management therapies currently available and a
desperate need for potentially better pain relief alternatives such as CBD oil. Therefore, more
research is obligatory to better understand its potential for efficacy, safety, and to define its role
in the management of rheumatic disease pain (Fitzcharles, 2016). It is also essential that future
research studies must astutely examine dosages and concentration as some research suggests
these are pivotal factors needed to determine efficacy and safety (Zuardi, 2008). Without a
doubt, future rigorous double-blind randomized placebo control trials aimed at determining the
short- and long-term efficacy and safety of CBD oil are desperately needed as patients are using
CBD products despite the lack of evidence.
Education Recommendations
There are more than one hundred known cannabinoids derived from the cannabis plant
but the most commonly known are THC and CBD. Due to popularity, the sale and use of these
products has grown significantly in recent years. Concerningly, this rapid increase has left many
patients and providers unclear about the ingredients in the numerous different cannabinoid
products available both over the counter and by prescription. As cannabinoid compounds vary in
their active ingredients and systemic effects, clear understanding of the commonly used
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cannabinoids is crucial for patients and providers. Therefore, education must be intended to
inform patients and providers about the different cannabinoid compounds sold, their effects, and
their respective the terminology. Furthermore, this education is essential for healthcare providers
in order to have a strong familiarity with each product and accurately provide patients with
information about cannabinoids when approached.
The regulation of cannabinoid products varies significantly at the federal and state level,
leading to ongoing confusion related to CBD oil legality. Furthermore, recent changes regarding
the growth of hemp plants for commercial cultivation leaves many unclear on whether CBD oil
from hemp is legal to be sold and consumed. Thus, dissemination of the current regulations of
these products should be done in order to provide patients and providers with clarity regarding
the legality of CBD oil in their state.
Oftentimes providers are questioned by patients about CBD oil use for pain relief.
However, because little evidence is known about the therapeutic benefit of CBD, doubt in its
effectiveness is presented. This cannabinoid skepticism, while fitting given the lack of evidence,
must be confronted in order to develop a greater understanding of the therapeutic role of CBD oil
(Sarzi-Puttini et al., 2019). It is important that providers to maintain mental flexibility and
openness to seeking safer and more effective alternatives for rheumatic disease pain as
conventional therapies are failing to provide adequate relief (Sarzi-Puttini et al., 2019). To
support this, providers must be educated on the current body of evidence, its recommendations,
and advocate for further rigorous research studies to be conducted in order to better guide
patients.
Ultimately, despite the lack of high-quality evidence, patients continue to use CBD oil for
rheumatic disease pain relief. With an open-minded approach, providers must use caution when
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recommending CBD oil to patients until additional studies have been conducted. To best guide
patients understanding, informed providers should share the findings from the current body of
evidence regarding the efficacy and safety of these products with patients. In addition, a
collaborative approach should be maintained if patients choose to use CBD oil in order to
maintain patient trust and safeguard quality of life.
Recommendations for Policy
Presently, no guidelines have been endorsed by a national guideline clearinghouse or
rheumatology association recommending CBD oil for the management of rheumatic disease pain
(Sarzi-Puttini et al., 2019). Furthermore, because of the lack of evidence some rheumatology
associations recommend against using cannabinoids for the treatment of pain associated with
rheumatological conditions including osteoarthritis (Sarzi-Puttini et al., 2019). At present time,
recommendations for policy changes cannot be made due to the lack of high-quality evidence
supporting CBD oil’s efficacy and safety for the treatment of rheumatic disease pain. Any
recommendations for future policy changes must be made based on rigorous evidence-based
studies as anecdotal testimony and expert advice is not enough to protect patients from any
unknown harmful effects.
Conclusion
The paucity of supporting evidence that exists leaves many questions unanswered
regarding CBD oil’s place in the clinical management of rheumatic disease pain. It is not a secret
that the current analgesic drugs are suboptimal at best for the management of rheumatic disease
pain (Sarzi-Puttini et al., 2019). Furthermore, some have even led to catastrophic health related
effects such as addiction and even death and have done little to improve the quality of life for
patients with rheumatic disease (Sarzi-Puttini et al., 2019). Taking this into consideration, safer
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alternative therapies for pain management are desperately needed as rheumatic diseases are
lifelong and require clinically proven safe analgesic drugs to safeguard quality of life (SarziPuttini et al., 2019). Thus, it is imperative to maintain openness to potentially safer alternatives
to rheumatic disease pain such as CBD oil. Now more than ever patients are seeking alternative
therapies for rheumatic disease pain, the necessity for rigorous clinical studies designed to
determine whether CBD oil is an effective and safe alternative has never been more imperative.
In conclusion, providers alike should take a careful approach regarding the use of CBD oil for
patients with rheumatic disease pain by limiting advocacy to those who have exhausted all other
pain relief options until additional high-quality evidence is readily available.
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Appendix
Table 1
Database Search Description
Database

Restrictions Added
to Search

CINAHL Plus
with Full Text

Full Text; English
Language; Peer
Reviewed; Abstract
Available; Adult;
Human

PubMed

Full Text; English
Language; Abstract
Available; Humans

2009-2019

CENTRAL

Full Text; English
Language; Peer
Reviewed; Research
Article; Abstract
available; Humans
Full Text; English
Language; Peer
Reviewed;
Systematic review;
Literature review;
Humans

2006-2019

Full Text; English
Language; Peer
Reviewed; Evidencebased Healthcare;
Scholarly Journals

2010-2019

PsycINFO

ProQuest Central

Dates
Included in
Database
2010-2019

2008-2019

General Subjects Covered by
Database
Provides full text access to 29
core nursing journals and 17
allied health disciplines. It
covers topics including nursing,
biomedicine, health sciences
librarianship,
alternative/complementary
medicine, consumer health.
PubMed includes the fields of
biomedicine and health, life
sciences, behavioral sciences,
chemical sciences, and
bioengineering. MEDLINE is
the primary component of
PubMed.
This database contains full text
articles and protocols focusing
on the effects of healthcare. It
contains evidence-based reports
of randomized controlled trials.
Provides access to international
literature in psychology and
related disciplines. It provides
high quality literature regarding
psychiatry, education, business,
medicine, nursing,
pharmacology, law, linguistics,
and social work.
Provides access to full text
articles from scholarly journals
in areas such as health and
medical, nursing and allied
health, science and technology
or social sciences.
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Table 2
Data Abstraction Process: Hits per Database
Date of
Search

Key Words

10/11/19 “Cannabidiol”
10/11/19 “CBD oil”
10/17/19 “Cannabidiol”
AND “joint Pain”
10/17/19 “Cannabidiol”
AND “Joint pain”
AND “Antiinflammatory”
10/18/19 “Cannabidiol”
AND “Arthritis”
10/18/19 “Cannabidiol”
AND “Rheumatic
disease”
10/22/19 “Cannabidiol”
AND “Rheumatic
disease” AND
“Antiinflammatory”
10/24/19 “Cannabidiol”
AND “Rheumatic
disease” AND
“Inflammation”
10/24/19 “Cannabidiol”
AND “Rheumatic
disease” AND
“Pain”
10/24/19 “Cannabidiol”
AND “Rheumatic
disease” AND
“Pain Relief”
10/24/19 “Cannabidiol”
AND “Rheumatic
disease” AND
“Analgesic”
10/24/19 “Cannabidiol” OR
“CBD Oil” AND
“Rheumatic
disease” AND

CINAHL PubMed CENTRAL PsycINFO ProQuest
Plus with
Central
Full Text
153
0
0

825
21
3

502
41
1

235
1
25

860
11
81

0

2

0

1

3

2

3

4

1

73

0

3

2

0

66

0

2

1

0

23

0

1

0

0

48

0

4

2

0

54

0

1

0

0

27

0

2

1

0

11

64

1

15

1

14
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“Antiinflammatory”
10/25/19 “Cannabidiol” OR 0
2
14
0
“CBD Oil” AND
“Rheumatic
disease” AND
“Inflammation”
10/25/19 “Cannabidiol” OR 17
3
16
1
“CBD Oil” AND
“Rheumatic
disease” AND
“Pain”
10/25/19 “Cannabidiol” OR 14
1
14
0
“CBD Oil” AND
“Rheumatic
disease” AND
“Pain relief”
10/25/19 “Cannabidiol” OR 14
2
15
0
“CBD Oil” AND
“Rheumatic
disease” AND
“Analgesic”
10/25/19 “Cannabidiol” OR 0
1
16
1
“CBD Oil” AND
“Rheumatic
disease” AND
“Treatment
efficacy”
*BOLD = articles reviewed for match with systematic review inclusion criteria

14

76

75

760

44
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Table 3
Characteristics of Literature Included and Excluded
Reference
Amin, M. R., & Ali, D. W. (2019). Pharmacology of
medical cannabis. Advances in Experimental
Medicine and Biology, 1162, 151-165.
https://doi.org/10.1007/978-3-030-21737-28
Ark, E. J. (2016). Cannabis Therapy in Patients with
Rheumatoid Disease. International Student Journal
of Nurse Anesthesia, 15(2), 92–101.

Included /
Excluded
Excluded

Rationale
Reviews the use of medical cannabis as a medicinal
agent in the treatment of pain and inflammation in
epilepsy and neurodegenerative diseases.

Included

Literature review of Level II and Level III studies
examining cannabis or cannabidiol use in rheumatoid
arthritis.

Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018).
Patterns of medicinal cannabis use, strain analysis,
and substitution effect among patients with
migraine, headache, arthritis, and chronic pain in a
medicinal cannabis cohort. Journal of Headache &
Pain, 19(1), 1. https://doi-org/10.1186/s10194-0180862-2

Excluded

Studies the use of medical cannabis for patients with
headache, arthritis, and chronic pain.

Blake, D. R., Robson, P., Ho, M., Jubb, R.W., & McCabe,
C.S. (2006). Preliminary assessment of the efficacy,
tolerability and safety of a cannabis-based medicine
(Sativex) in the treatment of pain caused by
rheumatoid arthritis. Rheumatology, 45(1), 50–52.
https://doi.org/10.1093/rheumatology/kei183

Included

Randomized control trial assessing the efficacy of
cannabis-based medicine for the treatment of pain due
to rheumatoid arthritis.

Booz, G. (2011). Cannabidiol as an emergent therapeutic
Included
strategy for lessening the impact of inflammation on
oxidative stress. Free Radical Biology and
Medicine, 51(5), 1054–1061.
https://doi.org/10.1016/j.freeradbiomed.2011.01.007

Literature review of the utility of non-psychotropic
cannabidiol in reducing oxidative stress and
inflammation in diseases such as rheumatoid arthritis
and neuropathic pain.
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Bruni, N., Della-Pepa, C., Oliaro-Bosso, S., Pessione, E.,
Gastaldi, D., & Dosio, F. (2018). Cannabinoid
delivery systems for pain and inflammation
treatment. Molecules: A Journal of Synthetic
Chemistry and Natural Product Chemistry, 23(10).
https://doi.org/10.3390/molecules23102478
Brunt, T. M., Van Genugten, M., Höner-Snoeken, K., Van,
D. V., & Niesink, R. J. M. (2014). Therapeutic
satisfaction and subjective effects of different
strains of pharmaceutical-grade cannabis. Journal of
Clinical Psychopharmacology, 34(3), 344-349.
https://doi.org/10.1097/JCP.0000000000000129
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010).
Therapeutical use of the cannabinoids in psychiatry.
Brazilian Journal of Psychiatry 32, S56-S65.
Farooqui, M. T., Khan, M. A., Cholankeril, G., Khan, Z.,
Abdul, M. K. M., Li, A. A., Shah, N., Wu, L., Haq,
K., Solanki, S., Kim, D., & Ahmed, A. (2019).
Marijuana is not associated with progression of
hepatic fibrosis in liver disease: a systematic review
and meta-analysis. European Journal of
Gastroenterology & Hepatology, 31(2), 149–156.
https://doi.org/10.1097/MEG.0000000000001263
Fitzcharles, M., Baerwald, C., Ablin, J., & Häuser, W.
(2016). Efficacy, tolerability and safety of
cannabinoids in chronic pain associated with
rheumatic diseases (fibromyalgia syndrome, back
pain, osteoarthritis, rheumatoid arthritis). The Pain,
30(1), 47–61. https://doi.org/10.1007/s00482-0150084-3

Included /
Excluded
Included

Rationale

Excluded

Measures the therapeutic effects of pharmaceuticalgrade cannabis.

Excluded

Reviews cannabinoids use in psychiatry.

Excluded

Study examines Marijuana and hepatic disease.

Included

A systematic review of RCTs focused on the treatment
of FMS, OA, and RA with herbal cannabis or
pharmaceutical cannabinoid products.

Explores the most current clinical trials in the
cannabinoid delivery field, focusing on pain and
inflammation treatment.
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Hendricks, O., Andersen, T.E., Christiansen, A.A.,
Primdahl, J., Hauge, E.M., Ellingsen T, Horsted, T.
I., Bachmann, A. G., Loft, A.G., Bojesen, A. B.,
Ostergaard, M., Hetland, M. L., Krogh, N. S.,
Roessler, K. K., & Petersen K. H. (2019). Efficacy
and safety of cannabidiol followed by an open label
add-on of tetrahydrocannabinol for the treatment of
chronic pain in patients with rheumatoid arthritis or
ankylosing spondylitis: protocol for a multicentre,
randomised, placebo-controlled study. British
Medical Journal Open, 9(6). https://doiorg/10.1136/bmjopen-2018-028197
Hunter, D., Oldfield, G., Tich, N., & Messenheimer, J.
(2018). Synthetic transdermal cannabidiol for the
treatment of knee pain due to osteoarthritis.
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Jehad, A. B., Korang, S. K., Feinberg, J., Maagard, M.,
Gluud, C., Mathiesen, O., & Jakobsen, J. C. (2019).
Cannabinoids versus placebo or no intervention for
pain: Protocol for a systematic review with metaanalysis and trial sequential analysis. British
Medical Journal Open, 9(10), e031574.
http://dx.doi.org/10.1136/bmjopen-2019-031574
Katz-Talmor, D., Katz, I., Porat-Katz, B., & Shoenfeld, Y.
(2018). Cannabinoids for the treatment of rheumatic
diseases — where do we stand? Nature Reviews.
Rheumatology, 14(8), 488-498.
https://doi.org/10.1038/s41584-018-0025-5

Included /
Excluded
Excluded

Rationale

Included

Evaluates the reduction of pain and inflammation in
osteoarthritis knee pain with CBD oil use.

Excluded

Proposes a protocol for systematic review of
cannabinoid studies.

Excluded

Review Medial Cannabis treatment for Rheumatic
disease.

Evaluates the efficacy and safety of medical cannabis in
the treatment of pain in patients with RA and AS with
low disease activity.
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Included /
Excluded
Included

Rationale

Excluded

A systematic review of clinical interventions that
increase the endocannabinoid system.

Included

Expert opinion on preclinical and human data regarding
the efficacy of cannabis in the treatment of joint pain.

Naftali, T., Mechoulam, R., Gabay, G., Stein, A.,
Bronshtein, M., Mari, A., & Konikoff, F.M. (2013).
Cannabidiol treatment does not affect active
Crohn’s disease. Gastroenterology, 144(5), S180.

Excluded

Examines CBD use in Crohn’s disease.

Pruskowski, J. (2019). Analgesic Effects of
Pharmaceutical-Grade Cannabis in Chronic Pain
Patients with Fibromyalgia. Journal of Pain and
Symptom Management, 58(3), 555–556.
https://doi.org/10.1016/j.jpainsymman.2019.07.001

Excluded

Reviews effects of pharmaceutical grade cannabis.

Reznik, S., Gardner, E., & Ashby, C. (2016). Cannabidiol:
A potential treatment for post Ebola syndrome?
International Journal of Infectious Diseases, 52,
74–76. https://doi.org/10.1016/j.ijid.2016.09.020
Zuardi, A. W. (2008). Cannabidiol: From an inactive
cannabinoid to a drug with wide spectrum of action.
Brazilian Journal of Psychiatry, 30(3), 271-280.

Excluded

Examines CBD use in post Ebola treatment.

Included

Describes the historical development of research and
current evidence on cannabidiol.

Kraft, B. (2012). Is there any clinically relevant
cannabinoid-induced analgesia? Pharmacology,
89(5-6), 237-46. https://doi.org/10.1159/000337376
McPartland, J. M., Guy, G. W., & Marzo, V. D. (2014).
Care and feeding of the endocannabinoid system: A
systematic review of potential clinical interventions
that upregulate the endocannabinoid system. Public
Library of Science One, 9(3).
http://dx.doi.org/10.1371/journal.pone.008956
Miller, R. J., & Miller, R. E. (2017). Is cannabis an
effective treatment for joint pain? Clinical and
Experimental Rheumatology, 107(5), 59-67.

Review of the analgesic properties of cannabinoids on
pain.
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http://dx.doi.org/10.1590/S151644462008000300015

Included /
Excluded

Rationale

Table 4
Literature Review Table of All Studies Included
Citation

Study Purpose

Pop (N) /
Sample
Size (n) /
Setting(s)

Ark, 2016

Literature review
of Level II and
Level III studies
examining
cannabis or
cannabidiol use in
rheumatoid
arthritis.

N/A

Blake et
al., 2006

Assesses the
efficacy of defined
dosages of
cannabis-based
medicine in
rheumatoid
arthritis pain.

n=58

Design/Level Variables /
of Evidence
Instruments
(Melnyk &
FineoutOverholt,
2015)
Level III,
N/A
Review of
RCT and NonRCT studies.

Findings

Implications

-Limited evidence
supports cannabidiol
for treatment of pain
caused by
inflammatory
pathways, autoimmune
processes, or
neurodegeneration.

Level II, RCT

-Cannabis-based
medicine produced
signiﬁcant
improvements in NRS
pain scores, sleep
quality and DAS28
scores.

More human
studies are
needed to
determine
efficacy in the
treatment of
rheumatoid
disease,
neuropathic and
autoimmune
pain.
Larger scale
research is
indicated.

Primary efﬁcacy
variable was pain
with movement
measured by a 0–10
numerical rating
scale (NRS) each
morning. Secondary
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Citation

Booz,
2011

Bruni et
al., 2018

Study Purpose

Pop (N) /
Sample
Size (n) /
Setting(s)

Reviews the utility
of nonpsychotropic
cannabidiol in
reducing oxidative
stress and
inflammation in
diseases such as
rheumatoid
arthritis and
neuropathic pain.

N/A

Review of current
clinical trials
regarding

N/A

Design/Level
of Evidence
(Melnyk &
FineoutOverholt,
2015)

Level VII,
Expert opinion
with
supportive
qualitative
evidence

Level III,

Variables /
Instruments

outcomes included
NRS measures of
pain at rest, sleep
quality and morning
stiffness. The ShortForm McGill Pain
Questionnaire (SFMPQ) and the 28joint disease activity
score (DAS28) were
also used.
N/A

Findings

Implications

-CBD attenuates
inflammation through
intracellular signaling
events.

The therapeutic
utility of CBD is
a relatively new
area of
investigation.
Additional
studies regarding
the effects of
CBD on
inflammation
and oxidative
stress are
needed.
Additional
evaluation of
Cannabidiol is

-CBD also has modest
antioxidant properties.

N/A

-Insufficient amounts
of rigorous clinical
studies have been
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Citation

Study Purpose

Pop (N) /
Sample
Size (n) /
Setting(s)

Design/Level
of Evidence
(Melnyk &
FineoutOverholt,
2015)
Review of
RCTs and
Non-RCTs

Variables /
Instruments

4 RCTs

Level I,
Systematic
Review of
RCTs

N/A

n=321

Level II, RCT

The primary efficacy
variable was a
change from baseline

cannabinoids and
their effects on
pain and
inflammation.

Fitzcharles A systematic
et al., 2016 review of four
RCTs regarding
treatment of FMS,
OA, and RA with
herbal cannabis or
pharmaceutical
cannabinoid
products.
Hunter et
Evaluates the
al., 2018
effects of CBD oil
on pain and

Findings

Implications

conducted regarding
cannabidiol and pain.
-Cannabinoids have
been associated with
an increased risk of
short-term side effects
-Clinical evidence to
date is confounded by
several factors,
including mixed
patient populations,
different cannabinoid
preparations, various
formulations, and wide
dosing ranges.
-There is insufficient
evidence to
recommend any
cannabinoid
preparations for
symptom management
of chronic pain
associated with
rheumatic diseases.
-After 12 weeks of
blinded treatment,
baseline pain NRS was

required to
determine
quality, safety
and efficacy
data.

Additional
control studies
are need.

Cannabidiol has
shown some
effect in
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Citation

Study Purpose

Pop (N) /
Sample
Size (n) /
Setting(s)

inflammation in
osteoarthritis the
knee.

Kraft,
2012

Explores the
clinical data in
cannabinoid use
for analgesia.

N/A

Design/Level
of Evidence
(Melnyk &
FineoutOverholt,
2015)

Level III,
Review of
RCT and NonRCTs

Variables /
Instruments

Findings

Implications

in the pain numeric
rating.

not statistically
different than placebo.

A key secondary
endpoint an average
weekly improvement
in worst pain score of
> 30% (responder
analysis) and
decrease in WOMAC
physical function at
least 20% at last
observation.
N/A

-Notably, men had
significantly decreased
worst pain score at
250mg /day than those
who received placebo.

reducing pain
and
inflammation but
additional well
controlled
studies
evaluating CBD
for osteoarthritis
(OA) in humans
are needed.

-Clinical data from
human trials is unclear
regarding the analgesic
effects of cannabinoids
on pain.
-Small sample sizes
and short trial duration
were a few variables
discovered that
impacted study
findings.

Additional welldesigned human
control studies
are needed to
confirm the
analgesic effects
of cannabinoids
on pain.

41
Citation

Miller &
Miller,
2017

Study Purpose

Historical review
of cannabis and
expert opinion on
current studies
assessing the
efficacy of
cannabinoids in
the treatment of
joint pain.

Pop (N) /
Sample
Size (n) /
Setting(s)

N/A

Design/Level
of Evidence
(Melnyk &
FineoutOverholt,
2015)

Variables /
Instruments

Level VII,
N/A
Expert opinion

Findings

-Cannabinoids
analgesia properties
are moderate to mild
and insufficient for the
treatment of severe
pain but may be useful
as adjuvant therapies.
-Rigorous clinical
evidence is not
available to support its
use in treating joint
pain.
-Numerous surveys
and qualitative
suggests patients
indicate benefit from
cannabinoid use.
-It is unclear if active
cannabinoids such as
THC are essential for
producing analgesic
effects or
if non-psychotropic
substances
such as CBD are also
helpful.

Implications

The effects of
herbal
cannabinoids in
humans with
joint pain needs
to be accurately
assessed.
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Citation

Study Purpose

Pop (N) /
Sample
Size (n) /
Setting(s)

Zuardi,
2008

Reviews the
historical
development of
research and
current evidence
on cannabidiol use
in numerous
diseases including
rheumatoid
arthritis, other
inflammatory
diseases.

N/A

Design/Level
of Evidence
(Melnyk &
FineoutOverholt,
2015)
Level VI,
Review of
case studies,
RCTs, and
Non-RCTs

Variables /
Instruments

Findings

Implications

N/A

-CBD has a wide
range of
pharmacological
effects for many
conditions including
rheumatoid arthritis.
-Study results of CBD
efficacy indicate the
dose is a pivotal factor
in future research.

Additional
randomized
clinical trials are
needed to
confirm
therapeutic
effects of CBD
oil and its
dosage.

